尼可拉维林（nicaraven）可以选择性地保护正常组织免受辐射引起的损伤。为了进一步开发尼可拉维林在减轻癌症放疗的副作用方面的临床应用，我们研究了尼可拉维林对辐射抑制肿瘤生长的潜在影响。我们通过在小鼠背部注射Lewis肺癌细胞，建立了皮下肿瘤模型。我们在胸部区域进行X射线照射，并分别通过腹腔注射不同剂量（0、20、50、100 mg/kg）的尼可拉维林进行术前或术后给药。肿瘤大小每隔一天进行测量。在第30天时，我们对小鼠进行了安乐死，并测量了肿瘤重量和肿瘤组织中的细胞因子水平。尼可拉维林的术前或术后给药，即使使用较高剂量（100 mg/kg），也没有显著减少辐射抑制肿瘤生长的效果。然而，术后给药20和50 mg/kg的尼可拉维林导致了相对较低的肿瘤重量。肿瘤组织中的IL-1β、IL-6、IL-10、MCP-1、MIP-2a、TGF-β1、VEGF、p53、p21、cyclin D1和caspase-3水平在尼可拉维林给药后未发生改变，并且与肿瘤重量没有显著相关。根据我们的实验数据，尼可拉维林在术前使用高剂量给药时，也不能显著减少辐射抑制肿瘤生长的效果。© 2023 Radiation Research Society.

Nicaraven selectively protects normal tissue from radiation-induced injury. To further develop the clinical application of nicaraven for mitigating the side effects of cancer radiotherapy, we investigated the potential effect of nicaraven administration in radiation-induced inhibition of tumor growth. A subcutaneous tumor model was established in mice by the injection of Lewis lung cancer cells at the back of the chest. X-ray radiation was delivered to the thoracic area and different doses of nicaraven (0, 20, 50, 100 mg/kg) were administrated intraperitoneally pre- or post-irradiation. The tumor size was measured every other day. Mice were euthanized on day 30, and the tumor weight and the levels of cytokines in tumor tissue were measured. Pre- or post-irradiation administration of nicaraven up to a dose of 100 mg/kg did not significantly diminish the radiation-induced inhibition of tumor growth, but post-irradiation administration of 20 and 50 mg/kg nicaraven resulted in relatively lower tumor weight. The levels of IL-1β, IL-6, IL-10, MCP-1, MIP-2a, TGF-β1, VEGF, p53, p21, cyclin D1 and caspase-3 in tumor tissue did not change by nicaraven administration and were not significantly associated with the tumor weights. According to our experimental data, nicaraven will not significantly diminish the radiation-induced inhibition of tumor growth, even with pre-irradiation administration at a high dose.© 2023 by Radiation Research Society.